Comparative Pharmacology
Head-to-head clinical analysis: PERIACTIN versus TRIPHED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERIACTIN versus TRIPHED.
PERIACTIN vs TRIPHED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyproheptadine is a first-generation antihistamine with anticholinergic and antiserotonergic properties. It acts as a competitive antagonist at histamine H1 receptors and serotonin 5-HT2 receptors, thereby inhibiting histamine-mediated allergic symptoms and serotonin-mediated effects such as increased gastrointestinal motility and vascular permeability.
Triprolidine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, thereby alleviating symptoms of allergic reactions. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing edema.
4 mg orally three times daily; adjust as needed. Maximum: 32 mg/day.
Adults: Triprolidine 2.5 mg / pseudoephedrine 60 mg orally every 4-6 hours, not to exceed 4 doses in 24 hours.
None Documented
None Documented
10-12 hours terminal elimination half-life; steady-state reached in 2-3 days
Terminal elimination half-life is 6-8 hours in adults with normal renal function; clinically, dosing interval adjustments are recommended in renal impairment.
Renal (40-50% as metabolites, <5% unchanged); biliary/fecal (minor, ~10-20%)
Renal excretion of unchanged drug and metabolites accounting for approximately 60-70% of elimination; biliary/fecal elimination accounts for 20-30%.
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination